Navigation Links
Fujirebio Diagnostics Announces FDA Clearance of Lumipulse G whole PTH Assay
Date:10/29/2019

Fujirebio Diagnostics, Inc., a consolidated subsidiary of Miraca Holdings Inc., has received U.S. Food and Drug Administration (FDA) clearance of the company’s Lumipulse® G whole PTH Assay for testing on its LUMIPULSE® G1200 immunoassay platform.

Parathyroid hormone (PTH) is a horomone secreted by the parathyroid glands; which are four small glands located behind the thyroid gland. The hormone regulates metabolism of Calcium and Phosphoric Acid in the body. The measurement of whole Parathyroid Hormone (wPTH or PTH (1-84)) using the Lumipulse® G whole PTH assay can be used in the differential diagnosis of hypercalcemia and hypocalcemia resulting from calcium metabolism disorders.

The Lumipulse® G whole PTH assay has a significant benefit over prior generation intact PTH assays currently used in most laboratories.The measurement of biologically active PTH (1-84) helps to understand parathyroid function without potential misclassification of the patients. There is no detectable cross reactivity to 7-84 and other PTH fragments observed with intact PTH (iPTH) assays; since whole PTH measures only the biologically active PTH and is 100% specific to whole PTH. Intact PTH can overestimate PTH indicated bone/mineral abnormalities because iPTH assays also detect various PTH fragements(1).

For Chronic Kidney Disease (CKD) patients not yet on dialysis (stage 3-5), The Clinical Practice Guideline CKD-MBD, Final Version (1/3/2015) recommends the measurement and monitoring of several tests including PTH as part of patient management. A falsely high PTH measurement due to a second generation iPTH test may result in falsely identifying a patient for dialysis.(2)

The Lumipule® G whole PTH is also traceable to in-house calibrators that have been assigned to the World Health Organization’s (NIBSC 95/646) standard; while iPTH assays are not standardized and their values can vary by manufacturer.

The Lumipulse® G whole PTH Assay on the Lumipulse® G1200 analyzer offers a fully automated assay with a reaction time of just 30 minutes; using a single test cartridge design for reagent stability, efficiency, and testing flexibility. The assay has demonstrated excellent precision with a CV of =4.0%.

“The Lumipulse® G whole PTH Assay is an innovative next-generation assay to help diagnose Calcium metabolism disorders, and to help monitor and adjust treatment of CKD patients.” says Matthew Bell, Vice President Sales and Marketing at Fujirebio, US.

About Fujirebio Diagnostics, Inc.
Fujirebio Diagnostics, Inc., a subsidiary of Fujirebio Holdings, Inc., is the premier cancer diagnostics company and the industry leader in cancer biomarker assays. The company pioneered and introduced the CA125 test, the first FDA-approved ovarian cancer biomarker over 25 years ago. Fujirebio Diagnostics specializes in the clinical development, manufacturing and commercialization of in-vitro diagnostic products for the management of human disease states, with an emphasis in oncology. For more information about Fujirebio Diagnostics, please call +1 610-240-3800 or visit us at https://www.fujirebio.com/en.

About Fujirebio
Fujirebio is a global leader in the field of high quality in vitro diagnostics (IVD) testing. It has more than 50 years’ accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products. Fujirebio has a strong and long-lasting tradition of collaborating with experts in the worldwide clinical community in the development of high-quality routine and truly novel biomarkers that cover a variety of disease states. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions.

Fujirebio is today a member of Miraca Group (Miraca Holdings Inc. listed on the Tokyo Stock Exchange – TYO: 4544) and employs more than 1,200 people in Asia, Europe and America.

(1) Kazama, J, Intact PTH assay overestimates true 1-84 PTH levels after maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism, Nephrology Dialysis Transplantation (2004) 19:892-897
(2) Priolo, G. Comparison between whole and intact Parathyroid Hormone assays, FRE-117, May 2017

Read the full story at https://www.prweb.com/releases/fujirebio_diagnostics_announces_fda_clearance_of_lumipulse_g_whole_pth_assay/prweb16681269.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. e3 Diagnostics and Bertec Partner to Provide Premier Balance Assessment and Rehabilitation Solutions
2. Molecular Diagnostics Market: 5 Things You Need to Know
3. Indivumed Partners with Flagship Biosciences to Provide Global Tissue-Based Diagnostics Services
4. VCU College of Engineering and Fuzionaire Diagnostics to Pursue Joint Research Applying Novel Radiochemistry Platform to Disease Diagnosis and Drug Discovery
5. uBiome Receives Patent for Microbiome-Derived Diagnostics and Therapeutics for Immune-Microbial Dysfunction
6. Nanomedical Diagnostics Announces Office Move to Accommodate Company Growth
7. LabRoots Produces 9th Annual Clinical Diagnostics & Research Virtual Conference Showcasing Developments in Laboratory Testing, Patient Care and Treatment
8. Abbott Diagnostics Features Advanced Optical Hematology Technology for Elevated Analytical Performance, in Informative Webinar
9. Combined with BONCAT, Nanomedical Diagnostics Graphene Biosensor Identifies Circulating Biomarkers of Aging
10. Fuzionaire Diagnostics Announces Disease-Agnostic Platform to Radiolabel Any Molecule for Disease Diagnosis and Drug Discovery
11. DNAnexus and QIAGEN Team Up in Education Webinar: Scaling End-to-End NGS Solutions for Clinical Diagnostics in the Cloud
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/11/2020)... ... March 11, 2020 , ... USARAD Holdings Inc., the leading ... several healthcare VC firms introduces a first of its kind COVID-19 screening program. ... has caused over 4,000 fatalities to date. Over the years, USARAD through its ...
(Date:3/10/2020)... ... March 10, 2020 , ... ... Board of Directors. Dr. Narasimhan is Senior Vice President of Strategic Initiatives, Portfolio ... the Board of Directors of Cytonus, we are extremely pleased to welcome Manisha ...
(Date:3/5/2020)... ... 2020 , ... With numerous products in its pipeline, Cytonus ... Cytonus’ existing products and to expand the companies’ intellectual property assets. Cytonus is ... located in Austria. , Phoenestra has developed IP assets in connection with ...
Breaking Biology News(10 mins):
(Date:3/19/2020)... ... March 17, 2020 , ... ... gene circuit company Senti Biosciences, Inc. (Senti) to accelerate the clinical translation ... indications. The collaboration will leverage RoosterBio’s human mesenchymal stem/stromal cell (hMSC) bioprocess ...
(Date:3/13/2020)... ... March 12, 2020 , ... ... APC Microbiome Ireland SFI Research Center (APC), a pioneer in the field of ... and play a significant role in human health, based at University College Cork ...
(Date:3/10/2020)... ... March 10, 2020 , ... Ortho Clinical Diagnostics, a global leader ... announced its ORTHOTM Sera, ID-MTS, a suite of extended antigen in a gel testing ... run on ORTHO VISION® and ORTHO VISION® Max in the United States and Canada. ...
(Date:3/10/2020)... Texas (PRWEB) , ... March 10, 2020 , ... ... facility on 13 acres in Cleburne, Texas to be used as a biopharmaceutical and ... its global headquarters and sales offices as well as its production and development hub. ...
Breaking Biology Technology: